Hypercalcemia of malignancy: Diagnosis and treatment options

American Journal of Cancer

Volumn 1, Issue 4, 2002, Pages 277-292

  Lamy, Olivier ^a   Burckhardt, Peter ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; FUROSEMIDE; GALLIUM NITRATE; HORMONE ANTIBODY; IBANDRONIC ACID; LOOP DIURETIC AGENT; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITHRAMYCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN ANTIBODY; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN ANTIBODY; PROTEIN ANTIBODY; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADVANCED CANCER; BLEEDING TENDENCY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; BREAST CANCER; CALCIUM BLOOD LEVEL; CLINICAL PRACTICE; CONFUSION; CONSTIPATION; DISEASE ASSOCIATION; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INCIDENCE; LIVER TOXICITY; LUNG CANCER; LYMPHOCYTOPENIA; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OSTEOLYSIS; PAIN; POLYDIPSIA; POLYURIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; REHYDRATION; REVIEW; SCLERITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STUPOR; SYMPTOMATOLOGY; THROMBOCYTE DYSFUNCTION; THROMBOPHLEBITIS; TREATMENT CONTRAINDICATION; UVEITIS; VOMITING;

EID: 0013405260     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200201040-00005     Document Type: Review

References (128)

1. Christensson T, Hellstrom K, Wengle B. Prevalence of hypercalcemia in a health screening in Stockholm. Acta Med Scand 1976; 200 (5): 131-7
2. Palmer M, Jakobsson S, Akerstrom G, et al. Prevalence of hypercalcemia in a health survey: a 14 year follow-up study of serum calcium values. Eur Clin Invest 1988 Feb; 18 (1): 39-46
3. Frolich A. Prevalence of hypercalcaemia in normal and in hospital populations. Dan Med Bull 1998 Sep; 45 (4): 436-9
4. Dent DM, Miller JL, Klaff L, et al. The incidence and causes of hypercalcemia. Postgrad Med J 1987 Sep; 63 (743): 745-50
5. Froelich A, McNair P, Transboel I. Awareness of hypercalcaemia in a hospital population? Scand J Clin Lab Invest 1991 Feb; 51 (1): 37-41
6. Fisken RA, Heath DA, Bold AM. Hypercalcaemia: a hospital survey. Q J Med 1980 Aut; 49 (196): 405-18
7. O'Rourke NP, McCloskey EV, Kanis JA. Tumour induced hypercalcemia: a case for active treatment. Clin Oncol 1994; 6 (3): 172-6
8. Firkin F, Seymour JF, Watson AM, et al. Parathyroid hormone-related protein in hypercalcaemia associated with haematological malignancy. Br J Haematol 1996 Sep; 94 (3): 486-92
9. Fisken RA, Heath DA, Somers S. Hypercalcaemia in hospital patients: clinical and diagnostic aspects. Lancet 1981 Jan 24; 1 (8213): 202-7
10. Burckhardt E, Kistler HJ. Hypercalciämie bei hospitalisierten Patienten. Schweiz Med Wochenschr 1981 Dec 19; 111 (51): 2017-23
11. Burt ME, Brennan MF. Incidence of hypercalcemia and malignant neoplasm. Arch Surg 1980 Jun; 115 (6): 704-7
12. Lamy O, Jenzer-Closuit A, Burckhardt P. Hypercalcemia of malignancy: an underdiagnosed and undertreated disease. J Intern Med 2001 Jul; 250 (1): 73-9
13. Roof BS, Piel CF, Hansen J, et al. Serum parathyroid hormone levels and serum calcium levels from birth to senescence. Mech Ageing Dev 1976 Jul-Aug; 5 (4): 289-304
14. Kaufmann-Didisheim N. Définition de l'intervalle de référence de la calcémie dans une population hospitalière [thesis]. Lausanne: University of Lausanne, 1989
15. Blomqvist CP. Malignant hypercalcemia: a hospital survey. Acta Med Scand 1986; 220 (5): 455-63
16. Vassilopoulou-Sellin R, Newman BM, Taylor SH, et al. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 1993 Feb 15; 71 (4): 1309-12
17. Heath DA. Hypercalcaemia in malignancy. BMJ 1989 Jun 3; 298 (6686): 1468-9
18. Warrel RP. Metabolic emergencies. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia (PA): Lippincott-Raven, 1997: 2486-93
19. Ralston SH, Gallacher SJ, Patel U, et al. Cancer-associated hypercalcemia: morbidity and mortality. Ann Intern Med 1990 Apr 1; 112 (7): 499-504
20. Geddes Jr LG, Dorn RA, Wadleigh RG. Hypercalcemia in patients with esophageal cancer. J Exp Clin Cancer Res 1999 Mar; 18 (1): 61-2
21. Won C, Decker DA, Drelichman A, et al. Hypercalcemia in head and neck carcinoma, incidence and prognosis. Cancer 1983 Dec 15; 52 (12): 2261-3
22. Iwase M, Kurachi Y, Kakuta S, et al. Hypercalcemia in patients with oral squamous cell carcinoma. Clin Oral Investig 2001 Sep; 5 (3): 194-8
23. Fukasawa H, Kato A, Fujigaki Y, et al. Hypercalcemia in a patient with B-cell acute lymphoblastic leukemia: a role of proinflammatory cytokine. Am J Med Sci 2001 Aug; 322 (2): 109-12
24. Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993 Sep 1; 82 (5): 1383-94
25. Thompson JT, Paschold EH, Levine EA. Paraneoplastic hypercalcemia in a patient with adenosquamous cancer of the colon. Am Surg 2001 Jun; 67 (6): 585-8
26. Mahadevia PS, Ramaswamy A, Greenwald ES, et al. Hypercalcemia in prostatic carcinoma: report of eight cases. Arch Intern Med 1983 Jul; 143 (7): 1339-42
27. Palmer FJJ, Nelson JC, Bacchus H. The chloride-phosphate ratio in hypercalcemia. Ann Intern Med 1974 Feb; 80 (2): 200-4
28. Choo-Kang E, Sennet M. Simple biochemical test to distinguish primary hyperparathyroidism from other cause of hypercalcaemia. West Indian Med J 1986 Mar; 35 (1): 58-60
29. Lind, L, Ljunghall S. Serum chloride in the differential diagnosis of hypercalcemia. Exp Clin Endocrinol 1991; 98 (3): 179-84
30. Hutchesson ACJ, Bundred NJ, Ratcliffe WA. Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism. Postgrad Med J 1995 Jan; 71 (831): 28-31
31. Mayer O, Hricko P, Bernhard P, et al. Fatal hypercalcemia in tamoxifen. Chief symptom: increasing somnolence in a 68-year-old patient. Schweiz Rundsch Med Prax 1999 Nov 11; 88 (46): 1923-4
32. Spooner D, Evans BD. Tamoxifen and life-threatening hypercalcaemia. Lancet 1979 Aug 25; II (8139): 413-4
33. Mulvenna PM, Wright AJ, Podd TJ. Life-threatening tamoxifen-induced hypercalcaemia. Clin Oncol 1999; 11 (3): 193-5
34. Nikolic-Tomasevic Z, Jelic S, Popov I, et al. Tumor 'flare' hypercalcemia: an additional indication for bisphosphonates? Oncology 2001; 60 (2): 123-6
35. Nussbaum SR. Pathophysiology and management of severe hypercalcemia. Endocrinol Metab Clin North Am 1993 Jun; 22 (2): 343-62
36. LeBoff MS, Brown EM. Clinical disorders of calcium metabolism. In: Hare JW, editor. Signs and symptoms in endocrine and metabolic disorders. London: JB Lippincott Company, 1986: 224-38
37. Juchet H, Ollier S, Micouleau X, et al. Hypercalcémies néoplasiques: facteurs pronostiques pour la survie des patients; à partir de 51 cas observés en médecine interne. Rev Med Intern 1993 Mar; 14 (3): 149-54
38. Merrill P. Oncologic emergencies. Lippincotts Prim Care Pract 2000; 4: 400-9
39. Wrede-Seaman LD. Management of emergent conditions in palliative care. Prim Care 2001 Jun; 28 (2): 317-28
40. De Wit S, Cleton FJ. Hypercalcemia in patients with breast cancer: a survival study. J Cancer Res Oncol 1994; 120 (10): 610-4
41. Brada M, Rowley M, Grant DJ, et al. Hypercalcemia in patients with disseminated breast cancer. Acta Oncol 1990; 29 (5): 577-80
42. Kristensen B, Ejlertsen B, Mouridsen HT, et al. Survival in breast cancer patients after the first episode of hypercalcaemia. J Intern Med 1998 Sep; 244 (3): 189-98
43. Rizzoli R, Thiebaud D, Bundred N, et al. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab 1999 Oct; 84 (10): 3545-50
44. Rankin W, Grill V, Martin TJ. Parathyroid hormone-related protein and hypercalcemia. Cancer 1997 Oct 15; 80 (8 Suppl.): 1564-71
45. Ishikawa H, Tanaka H, Iwato K, et al. Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1 beta osteoclast factor-induced bone resorption. Blood 1990 Feb 1; 75 (3): 715-20
46. Dunne FP, Lee S, Ratcliffe WA, et al. Parathyroid hormone-related protein (PTHrP) gene expression in solid tumours associated with normocalcemia and hypercalcemia. J Pathol 1993 Nov; 171 (3): 215-21
47. Moseley JM, Gillespie MT. Parathyroid hormone-related protein. Crit Rev Clin Lab Sci 1995; 32 (3): 299-343
48. Kremer R, Shustik C, Tabak T, et al. Parathyroid-hormone-related peptide in hematologic malignancies. Am J Med 1996 Apr; 100 (14): 406-11
49. Jüppner H, Abou-Samra AB, Freeman M, et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991 Nov 15; 254 (5034): 1024-6
50. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999 Oct; 140 (10): 4451-8
51. Body JJ, Dumon JC, Thirion M, et al. Circulating PTH-rP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy. J Bone Miner Res 1993 Jun; 8 (6): 701-6
52. Budayr AA, Zysset E, Jenzer A, et al. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein. J Bone Miner Res 1994 Apr; 9 (4): 521-6
53. Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumor-induced hypercalcemia. Lancet 1993 Jun 26; 341 (8861): 1611-3
54. Pecherstorfer M, Schilling T, Blind E, et al. Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab 1994 May; 78 (5): 1268-70
55. Blind E, Raue F, Meinel T, et al. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955. Horm Metab Res 1993 Jan; 25 (1): 40-4
56. Thiebaud D, Jaeger P, Burckhardt P. Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone. J Bone Miner Res 1990 Mar; 5 (3): 221-6
57. Seymour JF, Gagel RF, Hagemeister FB, et al. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med 1994 Nov; 121 (9): 633-40
58. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000 Jun 15; 88 (12 Suppl.): 2892-8
59. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 Apr 18; 89 (2): 309-19
60. Nosaka K, Miyamoto T, Sakai T, et al. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 2002 Jan 15; 99 (2): 634-40
61. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001 Dec 15; 98 (13): 3534-40
62. Roux S, Amazit L, Meduri G, et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 2002 Feb; 117 (2): 210-6
63. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001 Apr; 57 (4): 611-6
64. Michigami T, Ihara-Watanabe M, Yamazaki M, et al. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 2001 Feb 15; 61 (4): 1637-44
65. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol Vase 2001 Apr 1; 22 (4): 549-53
66. Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 2001 May; 7 (8): 613-35
67. Han JH, Choi SJ, Kurihara N, et al. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001 Jun 1; 97 (11): 3349-53
68. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000 Jul 15; 96 (2): 671-5
69. Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001 Dec; 108 (12): 1833-41
70. Wuster C, Schoter KH, Thiebaud D, et al. Methylpentylamino-propylidene-bisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone Miner 1993 Aug; 22 (2): 77-85
71. Pecherstorfer M, Herrmann Z, Body JJ, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996 Jan; 14 (1): 268-76
72. Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med 1981 Aut; 50 (200): 473-81
73. Suki WN, Yium JJ, Von Minden M, et al. Acute treatment of hypercalcemia with furosemide. N Engl J Med 1970 Oct 15; 283 (16): 836-40
74. Fleisch H. Bisphosphonates-preclinical. In: Fleisch H, editor. Bisphosphonates in bone disease: from the laboratory to the patient. 4th ed. San Diego (CA): Academic Press. 2000: 27-55
75. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000 Jun 15; 88 (12 Suppl.): 2961-78
76. Major PP, Lipton A, Berenson J, et al. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 2000 Jan 1; 88 (1): 6-14
77. Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcemia. Br J Cancer 1997; 75 (2): 295-300
78. Major P, Lotholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001 Jan 15; 19 (2): 558-67
79. Singer FR, Ritch PS, Lad TE, et al. Treatment of hypercalcemia of malignancy with intravenous etidronate: a controlled, multicenter study. Arch Intern Med 1991 Mar; 151 (3): 471-6
80. Ryzen E, Martodam RR, Troxell M, et al. Intravenous etidronate in the management of malignant hypercalcemia. Arch Intern Med 1985 Mar; 145 (3): 449-52
81. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992 Jan; 10 (1): 134-42
82. Warrell Jr RP, Murphy WK, Schulman P, et al. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 1991 Aug; 9 (8): 1467-75
83. O'Rourke NP, McCloskey EV, Vasikaran S, et al. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 1993 Mar; 67 (3): 560-3
84. Coukell AJ, Markham A. Pamidronate: a review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging 1998 Feb; 12 (2): 149-68
85. Purohit OP, Radstone CR, Anthony C, et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995 Nov; 72 (5): 1289-93
86. Leyvraz S, Hess U, Flesch G, et al. Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst 1992 May 20; 84 (10): 788-92
87. Zysset E, Ammann P, Jenzer A, et al. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy. Bone Miner 1992 Sep; 18 (3): 237-49
88. Rosen LS, Gordon D, Antonio BS, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer of osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001 Sep-Oct; 7 (5): 377-87
89. Thiebaud D, Jaeger P, Jacquet AF, et al. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol 1988 May; 6 (5): 762-8
90. Nussbaum SR, Warrell Jr RP, Rude R, et al. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 1993 Aug; 11 (8): 1618-23
91. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999 Nov; 21 (5): 389-406
92. Body JJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 2001 Aug; 28 (4 Suppl. 11): 49-53
93. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996 Feb 22; 334 (8): 488-92
94. Davenport A, Goel S, Mackenzie JC. Treatment of hypercalcemia with pamidronate in patients with end stage renal failure. Scand J Urol Nephrol 1993; 27 (4): 447-51
95. Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001 Jul; 12 (7): 1530-7
96. Rotstein S, Glas U, Eriksson M, et al. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases: a prospective randomised placebo-controlled multicentre study. Eur J Cancer 1992; 28A (4-5): 890-3
97. Jacobs TP, Siris ES, Bilezikian JP, et al. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphate. Ann Intern Med 1981 Mar; 94 (3): 312-6
98. Kanis JA, McCloskey EV, Clodronate. Cancer 1997 Oct 15; 80 (8 Suppl.): 1691-5
99. Walker P, Watanabe S, Lawlor P, et al. Subcutaneous clodronate. Lancet 1996 Aug 3; 348 (9023): 345-6
100. Walker P, Watanabe S, Lawlor P, et al. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann Oncol 1997 Sep; 8 (9): 915-6
101. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 2001 Jul; 88 (7): 701-7
102. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology: International Bone and Cancer Study Group. J Clin Oncol 1998 Dec; 16 (12): 3890-9
103. McCloskey EV, MacLennan IC, Drayson MT, et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma: MRC Working Party on Leukaemia in Adults. Br J Haematol 1998 Feb; 100 (2): 317-25
104. Body JJ. Current and future directions in medical therapy: hypercalcemia. Cancer 2000 Jun 15; 88 (12 Suppl.): 3054-8
105. Gucalp R, Theriault R, Gill I, et al. Treatment of cancer associated hypercalcemia: double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline only. Arch Intern Med 1994 Sep; 154 (17): 1935-44
106. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996 Dec 12; 335 (24): 1785-91
107. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001 Sep 27; 345 (13): 948-55
108. Coleman RE, Purohit OP, Vinholes JJ, et al. High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 1997 Oct 15; 80 (8 Suppl.): 1686-90
109. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000 Mar 1; 88 (5): 1082-90
110. Rizzoli R, Buchs B, Bonjour JP. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate, Int J Cancer 1992 Mar 12; 50 (5): 706-12
111. , Dooley M, Balfour JA. Ibandronate. Drugs 1999 Jan; 57 (1): 101-8
112. Schwetz BA. From the Food and Drug Administration: hypercalcemia of malignancy. JAMA 2001 Oct 3; 286 (13): 1569
113. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001 Apr; 91 (7): 1191-200
114. Djulbegovic B, Wheatley K, Ross J, et al. Bisphosphonates in multiple myeloma (Cochrane Review). Available in The Cochrane Library[database on disk and CDROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Oxford Update Software, 1997
115. Bilezikian J. Management of acute hypercalcemia. N Engl J Med 1992 Apr 30; 326 (18): 1196-203
116. Bower M, Stein RC, Hedley A, et al. The use of nasal calcitonin spray in the treatment of hypercalcaemia of malignancy. Cancer Chemother Pharmacol 1991; 28 (4): 311-2
117. Thiebaud D, Burckhardt P, Jaeger P, et al. Effectiveness of salmon calcitonin administered as suppositories in tumor-induced hypercalcemia. Am J Med 1987 Apr; 82 (4): 745-50
118. Fatemi S, Singer SR, Rude RK. Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. Calcif Tissue Int 1992 Feb; 50 (2): 107-9
119. Thiebaud D, Jacquet AF, Burckhardt P. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. Arch Intern Med 1990 Oct; 150 (10): 2125-8
120. Sekine M, Takami H. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia. Oncol Rep 1998 Jan-Feb; 5 (1): 197-9
121. Percival RC, Yales AJP, Grey RES, et al. Role of glucocorticoids in the management of malignant hypercalcemia [letter]. BMJ 1984 Aug 4; 289 (6440): 287
122. Jenzer A. La symptomatologie de l'hypercalcémie tumorale et son traitment [thesis]. Lausanne: University of Lausanne, 1997
123. Thurlimann B, Waldburger R, Senn HJ, et al. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized cross-over trial. Ann Oncol 1992 Sep; 3 (8): 619-23
124. Todd PA, Fitton A. Gallium nitrate: a review of its pharmacological properties and therapeutic potential in cancer related hypercalcaemia. Drugs 1991 Aug; 42 (2): 261-73
125. Warrell Jr RP, Israel R, Frisone M, et al. Gallium nitrate for acute treatment of cancer-related hypercalcemia: a randomized, double-blind comparison to calcitonin. Ann Intern Med 1988 May; 108 (5): 669-74
126. Capparelli C, Kostenuik PJ, Morony S, et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000 Feb 15; 60 (4): 783-7
127. Kukreja SC, Shevrin DH, Wimbiscus SA, et al. Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumours. J Clin Invest 1988 Nov; 82 (5): 1798-802
128. Ogata E. Parathyroid hormone-related protein as a potential target of therapy for cancer-associated morbidity. Cancer 2000 Jun; 88 (12 Suppl.); 2909-11